NBIS vs TMO: Which Is the Better Buy?
Side-by-side comparison of Nebius Group N.V. and Thermo Fisher Scientific Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-08-06.
Nebius Group N.V. · Technology
$218.99
+11.9% upside to fair value
Med Conviction
Grade C+
VS
Thermo Fisher Scientific Inc. · Healthcare
$464.61
+7.2% upside to fair value
Grade A
High Quality
QuantHub Verdict
NBIS has more upside to fair value
(+11.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
NBIS |
TMO |
| Current Price |
$218.99 |
$464.61 |
| Fair Value Estimate |
$245.00 |
$498.27 |
| Upside to Fair Value |
+11.9%
|
+7.2%
|
| Market Cap |
$52.6B |
$172.7B |
| Forward P/E |
—
|
25.2x
|
| EV / EBITDA |
—
|
19.1x
|
| Price / Sales |
59.9x
|
3.8x
|
| Price / FCF |
—
|
25.6x
|
| Revenue Growth YoY |
+684.0%
|
+6.2%
|
| Gross Margin |
48.0%
|
39.4%
|
| Operating Margin |
-68.8%
|
17.8%
|
| Return on Equity |
—
|
13.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
-4.7%
|
3.91%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Nebius Group is a fast-scaling neocloud GPU infrastructure provider spun out of Yandex's international assets, positioned at the center of the AI compute buildout with a validated capital relationship to Nvidia, which holds a 9.3% stake following a $2 billion investment. Revenue grew 684% year over year in Q1 2026 to $399 million, core AI cloud ARR reached $1.92 billion, and the company has locke…
Thermo Fisher Scientific is a leading healthcare company specializing in life science tools, diagnostics, and contract research and manufacturing services. It operates with a broad, multi-layered moat driven by scale, integration, and a long-tenured management team. The company exhibits solid fundamentals with a 13.3% ROE, 6.2% revenue growth, and 9.6% earnings growth in the most recent quarter. …
Accumulation Zones
| Metric |
NBIS |
TMO |
| Zone Low |
$184.00 |
$373.70 |
| Zone High |
$208.00 |
$423.53 |
| In Buy Zone? |
No
|
No
|